{
  "name" : "dacemirror.sci-hub.se_journal-article_fbd2659ab832d8208586c04d492040a0_ibrahim2018.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Curcumin marinosomes as promising nano-drug delivery system for lung cancer",
    "authors" : [ "Shaimaa Ibrahim", "Tatsuaki Tagami", "Toshihiro Kishi", "Tetsuya Ozekia" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "Contents lists available at ScienceDirect\nInternational Journal of Pharmaceutics\njournal homepage: www.elsevier.com/locate/ijpharm\nCurcumin marinosomes as promising nano-drug delivery system for lung cancer\nShaimaa Ibrahima, Tatsuaki Tagamia, Toshihiro Kishib, Tetsuya Ozekia,⁎\na Drug Delivery and Nano Pharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, Aichi 467-8603, Japan bNippon Suisan Kaisha, Nishi-Shimbashi Square, 1-3-1, Nishi-Shimbashi, Minato-ku, Tokyo 105-8676, Japan\nA R T I C L E I N F O\nKeywords: Antioxidant Curcumin Lung cancer Marinosomes Nano formulations Polyunsaturated fatty acid (PUFA)\nA B S T R A C T\nLung cancer is the major cause of cancer-related death worldwide. Curcumin attracted attention due to its promising anti-cancer properties, however its poor aqueous solubility and bioavailability have to be overcome. In the current study curcumin is encapsulated in krill lipids-based liposomes (marinosomes) to develop a potential anticancer therapy from low-cost and readily available nutraceuticals. Reflux followed by thin drug-lipid film method is used successfully to incorporate the drug into the liposomal membrane at high encapsulation efficiency (EE). The curcumin-loaded marinosomes (CURMs) showed a powerful antioxidant activity (EC50≒ 4 μg/mL). Additionally, CURMs exhibited good physicochemical and oxidative stability after eight weeks’ storage at 4 °C. Furthermore, CURMs exhibited sustained release of about 30% of their curcumin content under in vitro culture conditions at 37 °C after 72 h. Consequently, CURMs showed its maximum cytotoxic effect (IC50; 11.7 ± 0.24 μg/ml) after incubation for 72 h against A549 lung cancer cells. Additionally, CURMs inhibited the proliferation of HUVECs in a dose-dependent manner with IC50 of 2.64 ± 0.21 μg/ml after incubation for 24 h. The current study presents the CURM as a favorable in vitro drug delivery system to target cancer disease."
    }, {
      "heading" : "1. Introduction",
      "text" : "Lung cancer is the major cause of cancer-related deaths worldwide with the non-small cell lung cancer (NSCLC) accounts about 80% of all lung cancer cases. Surgical removal is the standard treatment for earlystage NSCLC with the danger of postoperative complications (National Comprehensive Cancer Networkuideline, 2018). Platinum-based chemotherapy and radiation are the standard therapies for advanced NSCLC. Radiation and chemotherapy may result in a lot of negative side effects, including renal and neurologic toxic effects, aplasia, pneumonitis and pericarditis. In order to augment tumor control and diminish chemotherapy side effects, potential alternatives and non-toxic therapies for lung cancer have to be continuing investigated.\nCurcumin, which is a polyphenolic hydrophobic natural compound derived from the rhizomes of Curcuma longa, has been used to treat various disorders due to its safety and cost-effectiveness. Curcumin has been reported to target several molecules involved in the multistep carcinogenesis (Mehta et al., 2014). Meaning that curcumin can target tumor suppressor genes, cyclooxygenases and lipoxygenases to induce anti-carcinogenic and anti-inflammatory effects (Hong et al., 2004). Curcumin also suppresses the expression of tumor necrosis factor alpha\nthat is an inflammatory cytokine to control the progress of most tumor cells. Additionally, curcumin modulates the expression of transcription factors to act as anti-proliferative, anti-inflammatory, anti-angiogenic and anti-metastatic agent (Balasubramanyam et al., 2004; Bharti et al., 2003; Bierhaus et al., 1997; Pendurthi and Rao, 2000; Shishodia et al., 2003). Together these studies implicate that curcumin could be a promising chemopreventive agent for lung cancer treatment. Despite the promising effects of curcumin against cancer and numerous diseases, its light sensitivity, poor solubility in aqueous medium and poor bioavailability are issues make it less useful as a therapeutic agent and have to be overcome in order to avail the entire benefits of this plant-extracted compound (Anand et al., 2007). Nano-formulations of curcumin using liposomes (Li et al., 2005), polymeric nanoparticles (Bisht et al., 2007), lipid nanoparticles (Sou et al., 2008), nanoemulsions (Ahmed et al., 2012), and cyclodextrins (Desai, 2010) have been extensively investigating in order to enhance drug solubility, bioavailability, the therapeutic efficacy and cause controlled release of the drug. Although promising were these attempts, they showed some disadvantages like excipients’ high cost, innate cytotoxicity or limited drug loading and entrapment efficiency. Consequently, the encapsulation of curcumin into naturally occurring compound could help to develop a potential\nhttps://doi.org/10.1016/j.ijpharm.2018.01.051 Received 8 December 2017; Received in revised form 19 January 2018; Accepted 28 January 2018\n⁎ Corresponding author. E-mail address: ozekit@phar.nagoya-cu.ac.jp (T. Ozeki).\nInternational Journal of Pharmaceutics 540 (2018) 40–49\nAvailable online 01 February 2018 0378-5173/ © 2018 Elsevier B.V. All rights reserved.\nT\nanticancer therapy from low-cost and readily available nutraceuticals. Marinosomes are marine lipid-based liposomes containing a high ratio of polyunsaturated fatty acids (PUFAs) (Moussaoui et al., 2002). Marine PUFAs are divided into two subgroups: omega-6 (n-6) and omega-3 (n-3) that are metabolized and stored in cell membrane phospholipids (Schmitz and Ecker, 2008). They influence membrane fluidity, regulate a wide range of functions in the body and correct development and functioning of the brain and nervous systems (Das, 2006). In marine lipids, extracted from marine organisms like krill, a large portion of n-3 PUFAs are bound to phospholipids and includes a higher content of n-3 long chain PUFAs such as eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) (Peng et al., 2003; Winther et al., 2011). Marine phospholipids have high bioavailability compared with triglyceride are efficiently taken up into body tissues (Wijendran et al., 2002). It is previously reported that a diet including high n-3 long chain PUFA, such as the Japanese and Mediterranean diets, has lower occurrence of cancer (Gerber, 2012). N-3 PUFAs have been used in the prevention and treatment of cancer through various mechanisms (Vaughan et al., 2013). A likely mechanism of cancer prevention through the anti-inflammatory properties of n-3 PUFAs has been reported (Alaarg et al., 2016). Other studies have reported different mechanisms of cancer prevention by n-3 PUFAs including apoptosis, inhibition of angiogenesis, inhibition of metastasis and others (Blanckaert et al., 2010; Iigo et al., 1997; Yin et al., 2017). Actually, n-3 PUFAs are not only beneficial in cancer treatment but also in other diseases that share the same common physiopathological features like unbalanced oxidative stress, inflammation and abnormal cell proliferation (Calder, 2012; Ross et al., 2001).\nDespite the promising effects of n-3 PUFAs against cancer and other numerous diseases, it has been reported that their effects are typically observed after long-term oral consumption at a relatively high amount (Geusens et al., 1994; Schmidt et al., 1992). The use of nanomedicine to increase the levels of n-3 PUFAs in inflamed tissues has been studied (Alaarg et al., 2016). Additionally, effective and low-cost anticancer combination drugs were developed from curcumin with other naturally occurring nutraceuticals (Choudhury et al., 2013). To benefit wholly from the effects of both n-3 PUFAs and curcumin, together nanomedicine with drug combination strategy will be used to propose a novel liposomal formulation of curcumin-loaded PUFAs liposomes (curcumin marinosomes; CURMs). Such liposomal formulation could improve the bioavailability of curcumin, causes controlled release and leads to increased stability, antioxidant and anticancer activity. In this study, the physicochemical characteristics of CURMs and their antioxidant activity are reported. Additionally, the growth-arresting effects of CURMs on adenocarcinomic human alveolar basal epithelial cells (A549) and human umbilical vein endothelial cells (HUVEC) are studied to demonstrate their potential benefit in the treatment of cancer."
    }, {
      "heading" : "2. Materials and methods",
      "text" : ""
    }, {
      "heading" : "2.1. Materials",
      "text" : "Curcumin was purchased from Sigma–Aldrich (St. Louis, MO, USA). Ethanol, chloroform and methanol were purchased from Wako Pure Chemical (Osaka, Japan). PBS tablets were purchased from Takara Bio Inc. (Shiga, Japan).\nThe natural lipid mixture extracted from krill was supplied by Nippon Suisan Kaisha (Tokyo, Japan). The lipid extract analyzed by Japan Food Research Laboratories (Tokyo, Japan) contained the following weight percentages: saturated fatty acids (14.4%), monounsaturated fatty acids (18.3%), polyunsaturated fatty acids (63.5%), and unidentified compounds which may contain inorganic metals, cholesterol, vitamin E, and dietary fibers (3.8%). The fatty acids composition was determined using hydrogen flame ionization detection-gas chromatograph method. The polyunsaturated fatty acids were found to contain n-3 PUFAs (51.4%) and n-6 PUFAs (3.1%). The n-3 PUFAs were\nfound to contain the following fatty acids: e.g. eicosapentaenoic acid (29.2%; EPA (n-3)), docosahexaenoic acid (12.7%: DHA (n-3)), octadecatetraenoic acid (3.7% (n-3)), docosapentaenoic acid (2.9% (n-3)). The monounsaturated fatty acids were found to contain the following fatty acids: palmitoleic acid (9.2% (n-7)), oleic acid (8.1% (n-9)) and others (1%). The saturated fatty acids were found to contain the following fatty acids: palmitic acid (7.5%), myristic acid (5.6%) and others (1.3%).\n2.2. Preparation of CURMs using the thin drug-lipid film hydration method\nCURMs were prepared by reflux followed by thin drug-lipid film hydration method, which mentioned in details in our previous study with some modification (Ibrahim et al., 2017). Krill lipids were taken with different weights (10, 15, 20, and 30mg) in a glass bottle and dissolved in chloroform/methanol mixture (2/1, v/v). Curcumin (1mg) was added to the lipid solution and the mixture was refluxed (tightly close the glass bottle and stir at a temperature of 50 °C for 2 h). The resultant clear solution was evaporated to provide thin lipid films that were placed under high vacuum for at least overnight to remove the residual solvent. The dried drug-lipid film was hydrated in HEPES buffered Saline (HBS) (20mM HEPES, 150mM NaCl, pH 7.5) to form multilamellar vesicles (MLVs). For the CURMs prepared using extrusion method, the MLVs were extruded (Mini-extruder, Avanti Polar Lipids, Alabaster, AL, USA) 10 times through two Whatman Nucleopore TrackEtched polycarbonate membranes (200 nm×10; GE Healthcare Life Sciences; Chicago, IL, USA) at 50 °C to decrease their sizes. For the CURMs prepared using sonication, the MLVs were sized using an ultrasonic homogenizer (UH-50; SMT Company, Tokyo, Japan). The prepared formulations were cooled on ice for 15min and unencapsulated curcumin was removed by centrifugation (1500g, 4 °C, 15min). The mean size and polydispersity index (PDI) were determined using a dynamic light scattering instrument (ZetaSizer Nano-ZS; Malvern Instrument Ltd., Malvern, U.K.). Zeta potentials were measured using ZetaSizer Nano ZS90 (Malvern). The encapsulation efficiency (EE) was calculated as described in Section 2.3."
    }, {
      "heading" : "2.3. Determination of the encapsulation efficiency (EE) of CURMs",
      "text" : "The concentration of the encapsulated drug was measured by absorbance at 425 nm using a UV–visible spectrophotometer (UV-1800, Shimadzu, Kyoto, Japan) after completely disrupting the liposomes using methanol. The absorbance was converted into drug concentration using a standard curve. The EE was calculated using the equation:\n= ×Encapsulation Efficiency EE Drug Encapsulated Total Drug( %) ( / ) 100"
    }, {
      "heading" : "2.4. Determination of the antioxidant activity of CURMs in detergent buffer solution",
      "text" : "The free radical scavenging activities of vitamin C, CURMs prepared by extrusion (CURME), CURMs prepared by sonication (CURMS), free curcumin (free-CUR) and free marinosomes (FMs) were determined using the 2,2-diphenyl-l-picrylhydrazyl (DPPH) assay as previously reported after modification (Aadinath et al., 2016). CURME, CURMS, and curcumin were prepared with different concentrations ranging from 1.56 μg/ml to 25 μg/ml, added to different test tubes and adjusted to 950 μl using detergent buffer. Vitamin C as positive control was dissolved in HBS buffer with concentration 1mg/ml as a stock, and then different concentrations ranging from 1.56 μg/ml to 25 μg/ml were prepared using the detergent buffer. This detergent buffer is HBS treated with 0.3% (v/v) Triton X-100 as previously reported after modification (Nicklisch and Waite, 2014). FMs were prepared at different concentrations of lipids ranging from 23.4 μg/ml to 375 μg/ml, which encapsulate the herein above-mentioned curcumin concentrations. Later 50 μl of 2 mM DPPH ethanolic solution was added to these\ntubes, the final concentration became 0.1mM DPPH. The tubes were shaken and allowed to stand at room temperature for 40min in dark condition. The control was prepared as mentioned above without the sample, and HBS-Triton mixture was used as a reference. A certain volume (230 μl/well) is transferred to 96-well plate and the absorbance was measured at 517 nm by using microplate reader (Wallac 4000 ARVO multi-label counter; PerkinElmer, Waltham, MA, USA). The antioxidant activity was calculated using the following formula:\n= − ×Antioxidant activity Abs control Abs sample Abs control% ( / ) 100\nwhere Abs control and Abs sample are the absorbance values of the control and sample respectively. The EC50 values, which are the concentrations of samples required to obtain 50% antioxidant activity, were determined based on the antioxidant activity curve using excel function tools."
    }, {
      "heading" : "2.5. Stability of CURMs under storage condition",
      "text" : "CURMs were stored at 4 °C. As a typical experiment, the samples were centrifuged (1500g, 4 °C, 15min) and aliquots were withdrawn at specified time points (0, 1, 2, 3, 4–8weeks) as reported previously (Chen et al., 2015). Variations in the particle size, PDI and curcumin retention were measured. Additionally, the oxidative stability was determined following the same procedure mentioned in Section 2.4. The curcumin retention percentage was determined using spectrophotometer as described in Section 2.3, and from the following equation as reported previously (Jin et al., 2016):\n= ×Curcumin retention CUR Retained CUR Encapsulated% ( / ) 100\nwhere CUR Retained is the amount of curcumin remained after the predetermined time and the CUR Encapsulated is the amount of curcumin that measured directly after preparation."
    }, {
      "heading" : "2.6. Retention of CURMs under culture condition",
      "text" : "To test the retention of curcumin under in vitro culture conditions, a series of test tubes were prepared. In every test tube, 100 μl of CURMs was mixed with 100 μl of DMEM (Wako Pure Chemical) supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and the samples were incubated at 37 °C in a humidified incubator in an atmosphere of 5% CO2/95% air. The samples were centrifuged (1500g, 4 °C, 15min), and the retention percentage was determined using spectrophotometer as described in Section 2.5."
    }, {
      "heading" : "2.7. Cells",
      "text" : "A549 cells were purchased from ATCC (Manassas, Virginia), maintained in DMEM (Wako Pure Chemical), and supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies, Carlsbad, California), 100 U/mL penicillin and 100 μg/mL streptomycin. Primary HUVECs were purchased from Lonza (Basel, Switzerland), and cultured in endothelial cell basal medium-2 (EBM-2, Lonza) containing fetal bovine serum, hydrocortisone, human fibroblastic growth factor, vascular endothelial growth factor, insulin-like growth factor, ascorbic acid, heparin, human epidermal growth factor and gentamicin/amphotericin-B. The cells were incubated at 37 °C in a humidified incubator in an atmosphere of 5% CO2/95% air."
    }, {
      "heading" : "2.8. Cytotoxicity study (WST Assay)",
      "text" : "The cytotoxicity of the CURMS, free curcumin solution (free-CUR), and free marinosomes (FMS) were evaluated using a Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan) as previously described after modification (Tagami et al., 2015). Briefly, A549 and HUVEC cells were prepared in medium, and seeded into 96-well cell incubation plate at a density of 5.0× 103 cells/well. A549 were pre-incubated for 48 h and\nthen treated with different concentrations (0, 10, 20, 30, 40 μg/ml) of CURMS. In addition, the cells were treated with free-CUR, as a positive control, that was dissolved in ethanol and diluted by medium to the desired concentrations (0, 10, 20, 30, 40 μg/ml) as previously reported after modification (Tagami et al., 2014). Furthermore, the cells were treated with FMS prepared with different concentrations of lipids (0, 150, 300, 450, 600 μg/ml) that encapsulate the herein above-mentioned concentrations of curcumin. Regarding to HUVEC, the cells were incubated with different concentrations (0, 1.56, 3.12, 6.25, 12.5 μg/ ml) of CURMS and free-CUR. The cells were also treated with FMS prepared with different concentrations of lipids (0, 23.4, 46.8, 93.75, 187.5 μg/ml) that encapsulate the specified concentrations of curcumin. After exposure to the drug for predetermined time intervals (24, 48, 72 h) the cells were washed with PBS. The PBS was aspirated and then 110 μl of the solution mixture (100 μl medium and 10 μl of CCK-8 solution) was added to the wells. After A549 cells were incubated for 1 h and HUVEC cells were incubated for 4 h, the absorbance was measured using microplate reader (Wallac 4000 ARVO multi-label counter; PerkinElmer, Waltham, MA, USA) at 450 nm. The cell viability and cytotoxicity were calculated after subtraction of the background absorbance of the medium from the total absorbance using the following equations:\n= ×Cell viability Experimental Abs Control Abs% ( / ) 100\nwhere Experimental Abs is the absorbance of the wells treated with different concentrations of the drug and Control Abs is the absorbance of the wells incubated only with medium. The IC50 value, which is the half maximal inhibitory concentration, was calculated through linear and nonlinear curve fitting that performed using excel function tools."
    }, {
      "heading" : "2.9. Statistical analysis",
      "text" : "All data shown here are represented in “mean value ± standard deviation (S.D.)”. The two-way ANOVA, with Bonferroni multiple comparison test, was used to assess statistical significance by using GraphPad Prism (GraphPad Software Inc., CA, U.S.A.)."
    }, {
      "heading" : "3. Results and discussion",
      "text" : "3.1. CURMs prepared using the thin drug-lipid film hydration method\nKrill lipids extract was reported to be the leading marine phospholipid product on the market with approximately 35% phospholipid (Neptune Technologies & Bioressources, 2001). In addition, It was reported that almost half the lipid content of Krill presents in a phospholipid form, mainly phosphatidylcholine (Castro-Gómez et al., 2015). Phospholipid has a special molecular structure, which contains both hydrophilic head group and lipophilic fatty acid group. Subsequently, phospholipids have a good emulsifying properties and could be used as natural surfactants to prepare emulsion without addition of other emulsifiers (Lu et al., 2012). Additionally, it was reported that the marine extracted lipids have a potential oxidative stability to prepare liposomes (Lu et al., 2011). Consequently, in the present study the preparation of marinosomes from krill lipid extract and the loading of curcumin at reasonable drug-to-lipid ratios are accomplished. CURMs were prepared by incorporating the drug into the lipid phase using the thin drug-lipid film method after refluxing the drug with the lipids for 2 h. CURMs have liposome-like vesicle structure because of self-assembly property of phospholipids molecules. In reflux, it seems that raising the temperature melted the lipids and led to dissolve the curcumin into the lipid phase (Maiti et al., 2007). Additionally, curcumin could undergo hydrophobic interaction through its aromatic rings and hydrogen bonding through its phenol rings (Began et al., 1999). Therefore, the encapsulation efficiency of curcumin into the lipid phase increased. The four formulations of CURM and FM prepared by extrusion (FME and CURME) in this experiment are shown in Table 1. The\nCURME formulations have uniform sizes ranging from 101 ± 6.7 nm to 120.3 ± 3.7 nm, and a zeta potential values ranging from -13.2 ± 2.2mV to -14.8 ± 1.2mV. The particle size distribution of FME and CURME has a single peak, as shown in Fig. 1A and B, with a narrow size distribution (PDI < 0.117). However, as shown in Table 2, the four formulations of CURMs and FMs prepared by sonication method (CURMS and FMS) have uniform sizes ranging from 60.1 ± 3.4 nm to 94.4 ± 3.7 nm, and zeta potential values ranging from −13.0 ± 0.9mV to −14.9 ± 1.7mV. The particle size distribution of FMS and CURMS has a single peak, as shown in Fig. 1C and D, with a slightly wider size distribution (PDI < 0.265) compared to that of FME and CURME. In the extrusion method, increasing the lipid/ curcumin ratio does not show significant effects on particle size, PDI, and zeta potential, as shown in Table 1. This is not surprising, as it is well known that the extruded vesicles would be close in diameter to the pore size of the polycarbonate membranes used to prepare them (MacDonald et al., 1991). Additionally, the difference in the particle size between CURME 15 and FME is likely due to the variability of manual pressure applied during the extrusion. Particularly, CURME 10 and FME have nearly similar particle sizes. However, in sonication method the lipid/curcumin ratio affects the particle size of CURMS, as shown in Table 2. As the lipid/curcumin ratio increases from 10/1 to 30/1 the particle size decreases from 94.4 ± 3.7 to 60.1 ± 3.4 nm, respectively, in agreement with what is previously reported (Anuchapreeda et al., 2011). The relatively high power of sonication made the sizes of FMS and CURMS smaller than those of FME and CURME. In Table 2, it is worthy to note that there is a clear difference in particle size between FMS and CURMS 15 (62.8 ± 2.3 nm and 81.0 ± 2.7 nm, respectively). This could be due to the incorporation of curcumin in the lipid layer of the liposomes. The curcumin was present in molecule or partially crystalized solid state. The curcumin could affect the membrane fluidity of lipid nanoparticles, preventing the pulverization of nanoparticles by sonication. The negative charge of zeta potential values, shown in Table 2, could be due to the partition of the negatively charged phospholipids and free fatty acids into the lipid layer."
    }, {
      "heading" : "3.2. Encapsulation efficiency (EE) of CURMs",
      "text" : "The EE measurement of CURMs was shown in Fig. 2. When the CURMs were centrifuged to separate the excess curcumin after preparation, pellets of excess curcumin were seen only at low lipid weight (10mg/ml). So, we skipped the other condition (e.g. lipid weight is 5 mg/ml). We believe that the EE at lower lipid weight must be lower. We got the enough EE at 15mg/ml and there was not remarkable change observed (among 15mg/ml, 20mg/ml and 30mg/ml). The EE level was saturated on this level. Additionally, the sonication and the extrusion methods resulted in almost the same EE."
    }, {
      "heading" : "3.3. Determination of the antioxidant activity of CURMs in detergent buffer",
      "text" : "In food and biological extracts, the standard DPPH (1,1-diphenyl-2picryl-hydrazyl) assay is accustomed to be used for the in vitro\ndetermination of antioxidant activity (Prior et al., 2005). The interaction kinetics of DPPH assay with polyphenolic and non-phenolic compounds have been recently well studied (Villaño et al., 2007). In case of curcumin, DPPH scavenging is accelerated by hydrogen atom transfer or sequential proton loss electron transfer mechanism (Feng and Liu, 2009). However, it is well known that the DPPH assay uses methanol, ethanol or buffered alcoholic to keep the DPPH soluble for the in vitro determination of antioxidant activity. The DPPH scavenging activity of CURMs has to be tested in buffer to mimic the in vivo environment, while the DPPH is insoluble and unstable in buffer solutions. In the present study, a simple in vitro method to measure the antioxidant activity of liposomal formulations in buffer is used following a recent report after modification (Nicklisch and Waite, 2014). In a preliminary experiment, 0.3% Triton X-100 was selected to keep 100 μM DPPH soluble and stable in HBS buffer for up to 40min, which is the needed time to measure the antioxidant activity. The absorbance of DPPH in the HBS-Triton mixture is reduced to 80% after 180min, shown in Supplementary Fig. 1. If more time is needed, other detergents or buffers have to be tested first. The surfactant molecules form micelles at critical micelle concentration, this could help to dissolve and stabilize the hydrophobic molecules that are sparingly soluble in aqueous solutions. After determination of the antioxidant activity of ascorbic acid as a positive control using HBS-Triton mixture, shown in Table 3, we found that EC50 values agree with what was reported previously using methanol or buffered methanol solution (Sharma and Bhat, 2009). In Fig. 3, increasing the sample concentration resulted in increasing the antioxidant activity, which reveals a dose-dependent antioxidant activity. CURME and CURMS showed strong DPPH radical scavenging abilities. The antioxidant activities (at 25 μg/mL) of CURME and CURMS are 91.1% ± 0.3% and 89.5% ± 2.5%, respectively, that are as high as that of vitamin C (82.9% ± 5.8%) and clearly higher than that of curcumin (69.8% ± 7.6%). This indicates that CURMs possibly react, as electron donors, with free radicals and thus convert them into more stable compounds and stop further radical reactions.\nIn addition, the EC50 values of CURME and CURMS are 4.0 ± 0.9 μg/mL and 4.3 ± 1.8 μg/mL, respectively, which are nearly similar to that of vitamin C (4.5 ± 1.1 μg/mL) and significantly lower than that of curcumin (13.6 ± 2.8 μg/mL), shown in Table 3. Furthermore, the curve of the antioxidant activity of CURMs reached nearly a stationary phase at a relatively low concentration (12.5 μg/ mL). Consequently, CURMs could be considered as powerful antioxidants with a very high reactivity with free radicals. A synergistic antioxidant effect of phospholipid on α-tocopherol was previously reported (Cho et al., 2001). Subsequently, the increasing of the CURMs antioxidant activity compared to free-CUR could be explained due to a presumably synergistic antioxidant effect of phospholipid on curcumin."
    }, {
      "heading" : "3.4. Stability of CURMs under storage condition",
      "text" : "Physical instability leads to fusion of vesicles or leakage of the encapsulated drug. Additionally, curcumin undergoes fast hydrolytic degradation under basic and neutral pH conditions, which results in low pharmacological activities (Chen et al., 2015). Therefore, the storage stability is an important issue for drug delivery formulations. In the present study, the physical stability of CURME, CURMS and FME including particle size, PDI, and curcumin retention was investigated. Additionally, since the antioxidant capacity and free radical scavenging ability could be gradually lost during the storage, they have to be measured during and after the storage period. CURME, CURMS, and FME (lipid/drug ratio 15/1 w/w) were stored at 4 °C for eight weeks. Fig. 4A and 4B reveal that the mean particle diameter and PDI of CURME, CURMS and FME did not change significantly during 8 weeks. Fig. 4C shows that the retention rate of curcumin in CURME and CURMS slightly decreased to 89.5 ± 2.5% and 92.7 ± 1.9% of their initial values, respectively, after storage of 8 weeks. Additionally, no significant change in the antioxidant activity of CURME, CURMS, and\nFME (91.7 ± 0.13, 91.8 ± 0.18 and 26.8 ± 1.4, respectively) after storage of 6 weeks at 4 °C as shown in Fig. 4D. However, the oxidative stability of CURME and CURMS slightly decreased to 78.7 ± 2.5% and 79.0 ± 2.7%, respectively, after storage of 8 weeks. This decrease could be due to the decrease in the retained curcumin amount (about 10%, shown in Fig. 4C) after storage of 8 weeks. Particularly, the oxidative stability of FME shows no significant change after storage of 8 weeks. This could imply the utility of marinosomes to incorporate\nhydrophobic drugs and CURMs possess a favorable physical stability when stored at 4 °C. The physical stability of marine liposomes may be attributed to four different factors. The first, the storage at low temperature (4°C) inhibits the membrane fluidity of the nanoliposomes The second, the presence of cholesterol in marine lipids may increase the rigidity of marinosomes due to the resistance of cholesterol-incorporated liposome toward degradation (Grit et al., 1993). The third, the negative charges of phospholipids contribute to electrostatic\nstability (Lu et al., 2012). The fourth, the presence of free fatty acids in the marine lipids and their distribution in the lipid layer of marinosomes increase the negative surface charge in agreement with a previous report which showed that the incorporation of alkali fatty acids with phospholipid had a positive influence on the surface charge of O/\nW emulsion (Buszello et al., 2000). Additionally, the oxidative stability of marine liposomes could be attributed to three different factors. The first, the presence of PUFAs in the sn-2 position of the phospholipids may forbid oxygen and free radicals to attack PUFAs due to this tightly packed molecular conformation (Applegate and Glomse, 1986). The second, the presence of other antioxidant compounds like astaxanthin and α-tocopherol that are potent antioxidants (Castro-Gómez et al., 2015). The third, the presumably synergistic antioxidant effect of phospholipid and α-tocopherol (Cho et al., 2001)."
    }, {
      "heading" : "3.5. Retention of curcumin into marinosomes under cell culture condition",
      "text" : "A drug release study was carried out in a medium containing fetal bovine serum to mimic in vivo conditions. In the present study, because of the curcumin hydrolytic degradation, curcumin retention has been measured instead of drug release measurements to study the in vitro drug release. In case of CURMs (lipid/drug ratio of 15/1 w/w), curcumin retention undergoes initial decrease to reach 80.5 ± 5.5% (CURME) and 88.8 ± 7.9% (CURMS) of its initial value after 4 h as shown in Fig. 5. Afterward the curcumin retention continued in gradual decrease to 70.1 ± 5.2% (CURME) and 75.6 ± 1.1% (CURMS) during 72 h. The reason behind the high decrease rate of curcumin retention during the early stage of the measurement (∼4 h) is possibly the adsorption of some drug molecules on the surface of CURMs during the thin film preparation. It is well known that increasing the content of PUFA leads to increasing the fluidity of liposomes under physiological conditions compared to that of the saturated lipids (Saiz and Klein, 2001). Krill lipid is a mixture of saturated fatty acids, monounsaturated fatty acids, poly-unsaturated fatty acids, cholesterol and others as mentioned in Section 2.1. In addition, nearly half of the PUFAs of krill lipid are located in phospholipids (mainly phosphatidyl-choline) as it is previously reported (Castro-Gómez et al., 2015; Lu et al., 2011). Consequently, increasing the temperature to body temperature leads to increase the fluidity of marinosomes due to the presence of PUFAs and thus the curcumin release starts. However the presence of saturated fatty acids, phospholipids and cholesterol in krill lipid prevents marinosomes from complete fluidity and thus resulted in a controlled release phenomenon. The drug release is sustainable (0–30% at 0–72 h), shown in Fig. 5, denoting the significance of marinosomes as a drug delivery system. It is possible that 30% of the drug undergoes burst release and controlled release from the outer layer of the marinosomes. This result opens the door widely to the in vitro anticancer experiment to thoroughly investigate the controlled release of these formulations as discussed herein after."
    }, {
      "heading" : "3.6. The cytotoxicity of free and curcumin-loaded marinosomes on A549 cells",
      "text" : "A comparative cytotoxicity study to prospect the capability of CURMS to deliver highly hydrophobic drugs such as curcumin to lung cancer cells has been performed. A549 cells were treated separately with free-CUR as drug solution, CURMS and FMS for different times and concentrations. The effect of controlled release of curcumin under culture condition (Section 3.4.) was confirmed when cancer cells were used.\nFig. 6A shows cytotoxicity after incubation with A549 cells for 24 h, free-CUR has a cytotoxic effect of 63.4 ± 6.5% (the highest) while CURMS shows only 10.9 ± 5.9% at 20 μg/mL of curcumin concentration. At incubation time equal to 48 h, free-CUR and CURMS show nearly the same cytotoxic effect of 59.3 ± 4.0% and 55.7 ± 2.5% at 20 μg/mL, respectively, shown in Fig. 6B. However, when the incubation time is extended to 72 h, the cytotoxic effect of CURMS increased to 90.9 ± 2.2% (the highest) and that of free-CUR\ndecreased to 45.7 ± 9.2% at the same curcumin concentration (20 μg/ mL) as clearly shown in Fig. 6C. The IC50 values of free-CUR are 14.3 ± 5.1, 18.2 ± 2.9 and 19.8 ± 2.3 μg/ml at 24, 48 and 72 h, respectively, stated in Table 4. This means that free-CUR gives its ultimate effect on the cell during the early stage of the experiment and this may be due to the passive diffusion and accumulation of curcumin directly at its action site (Mohanty et al., 2010). While the IC50 values of CURMS are 35.0 ± 1.1, 19.9 ± 1.03 and 11.7 ± 0.24 μg/ml at 24, 48 and 72 h, respectively. This result clearly indicates the sustained release of curcumin from marinosomes over time that agrees with previous reports (Ma et al., 2007; Mohanty et al., 2010). It is worthy to notice that the cytotoxic effect of FMs is only clear at higher marinosomal doses (450 and 600 μg/ml) in a time- and dose-dependent manner.\nIt has been reported that PUFAs are taken up by tumors for use as precursors for biochemical metabolic pathways and energy production (Sauer and Dauchy, 1992). Once taken up, they are incorporated in the cellular membranes of the tumor and contribute to membrane fluidity, ion permeability and elasticity (Merendino et al., 2013). Plasma membrane is composed of microdomains that include structures known as lipid rafts and caveolae, which are rich in cholesterol and sphingolipids, and play a key role in cell signal transduction (Ma et al., 2004). The inclusion of n-3 PUFAs in tumor cell membranes, especially microdomains, may affect physicochemical properties of membranes due to their high unsaturation. This could explain the capability of n-3 PUFAs to induce cytotoxic effect in tumor cells through the regulation of multiple cellular functions (D’Eliseo and Velotti, 2016). This unique property of tumor biochemistry or physiology could be used to target tumors and increase the therapeutic effect of a chemotherapy with less side effect (Bradley et al., 2001; Kuznetsova et al., 2006).\nIt was reported that at a relatively high concentration (above 15 μg/ ml) of curcumin-loaded micelles, the cytotoxic effect was reduced due to saturation of the endocytic process which resulted in reduced drug entry (Ma et al., 2007; Mohanty et al., 2010). However, the current study shows that the cytotoxicity of CURMS at such high concentrations increases in a time dependent manner. The cytotoxicity of CURMS at 30 and 40 μg/ml is 96.60 ± 0.17%, and 96.63 ± 0.16% after 72 h. This could be due to the affinity of PUFAs to microdomains that may lead to incorporation of the marinosomes into the plasma membrane and enhance the internalization of curcumin. Additionally, A549 cells were reported to employ multiple endocytotic pathways (Kuhn et al., 2014) that possibly localize CURMs in intracellular vesicles. Afterword, a gradual release of curcumin from CURMs occurred resulted in a controlled release of curcumin."
    }, {
      "heading" : "3.7. The effect of free and curcumin-loaded marinosomes on HUVECs",
      "text" : "The formation of new blood vessels is a natural process called angiogenesis and it is essential during wound healing and embryonic development (Madri et al., 1991). However, many pathologies, including tumor growth, are arising from uncontrolled angiogenesis (Carmeliet, 2003). Endothelial cells are among the essential cells that\nconstitute the dynamic environment of tumors as they form the blood vessels. It was reported that curcumin is able to inhibit the proliferation of HUVECs and act as anti-angiogenic compound (Thaloor et al., 1998). In addition, it was reported that n-3 PUFAs have anti-angiogenic effect (Szymczak et al., 2008). Consequently, the time- and dose-response of CURMS, FMS and free-CUR on HUVEC growth were investigated in the present study. CURMS inhibited the proliferation of HUVECs in a dosedependent manner as shown in Fig. 7. The highest cytotoxic effect of CURMS and free-CUR were observed at 6.25 μg/mL after 24 h (85.2 ± 1.1% and 50.2 ± 4.5%, respectively), shown in Fig. 7A. Additionally, The IC50 values of CURMS and free-CUR at 24 h are (2.64 ± 0.21, 5.73 ± 2.1 μg/ml, respectively, shown in Table 4. The highest cytotoxic effect of FMS is (44.7 ± 8.7%) at concentration of 187.5 μg/ml after 48 h, and this could be due to the low concentrations of lipids that were used in this experiment.\nThe trends of the cytotoxic effects of CURMS, shown in Fig. 7, don't indicate obvious change in the cell viability after incubation for> 24 h\n(Fig. 7B and C), and thus no controlled release has been observed in this case. It was reported that the cellular membrane of endothelial cells is high in caveolae (Cohen et al., 2004) and that HUVEC cells express more caveolins than others (Voigt et al., 2014). This observation is previously used to target HUVEC cells using negatively charged lipid nanoparticles, without the need for cell-specific targeting ligands, depending on the high affinity of the lipophilic nanoparticles for caveolae (Voigt et al., 2014). This could lead to a high incorporation of CURMS into caveolae and a fast release of curcumin inside the HUVEC cells, and thus the ultimate cytotoxic effect occurred directly after incubation for 24 h. However, further experiments to determine the uptake pathways of A549 and HUVEC cells for CURMs are considered to be future aspects of study."
    }, {
      "heading" : "4. Conclusion",
      "text" : "The present study exhibits the encapsulation of curcumin into krill lipid-based liposomes through utilizing a modified thin drug-lipid film hydration method followed by extrusion or sonication. CURMs of uniform diameter, and narrow PDI were prepared with high encapsulation efficiency (> 90%) at a lipid/drug ratio of 15/1 (w/w). This approach resulted liposomal formulations of high physicochemical and oxidative stability. The krill lipids-based curcumin-loaded liposomes prepared in this study exhibited an effective cytotoxic effect after 72 h on A549 cells due to the controlled release phenomenon and after 24 h on HUVEC cells. These nano-nutraceutical liposomal formulations represent lowcost drug delivery systems that could be applied for efficient solubilization, stabilization and controlled delivery of the biological active and hydrophobic compounds for cancer and other inflammatory diseases targeting. However, exact mechanism by which CURMs exert antioxidant and anticancer effect is not elucidated in the present work. Furthermore, other functionalities of marinosomes relevant to biopharmaceutical field like controlled release, solubilizing other hydrophobic drugs, combination therapy and in vivo anticancer activity are future aspects of study."
    }, {
      "heading" : "Acknowledgments",
      "text" : "According to the measurement of zeta potentials, authors are grateful to Dr. Noriko Ogawa, Dr. Chisato Takahashi who are the members of Dr. Hiromitsu Yamamoto’s lab (Aichi-Gakuin University). In addition, we would like to thank Dr. Ashraf Abdel Haleem (Fayoum University, Egypt) for his assistance in physical and mathematical issues included in the manuscript."
    }, {
      "heading" : "Appendix A. Supplementary data",
      "text" : "Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.ijpharm.2018.01.051."
    } ],
    "references" : [ {
      "title" : "Synergistic radical scavenging potency of curcumin-in-β-cyclodextrin-in- nanomagnetoliposomes",
      "author" : [ "W. Aadinath", "A. Bhushani", "C. Anandharamakrishnan" ],
      "venue" : "Mater. Sci. Eng. C Mater. Biol",
      "citeRegEx" : "Aadinath et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Aadinath et al\\.",
      "year" : 2016
    }, {
      "title" : "Nanoemulsion- and emulsion-based delivery systems for curcumin: encapsulation and release properties",
      "author" : [ "K. Ahmed", "Y. Li", "D.J. McClements", "H. Xiao" ],
      "venue" : "Food Chem",
      "citeRegEx" : "Ahmed et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Ahmed et al\\.",
      "year" : 2012
    }, {
      "title" : "Docosahexaenoic acid liposomes for targeting chronic inflammatory diseases and cancer: an in vitro assessment",
      "author" : [ "A. Alaarg", "N. Ordan", "J. Verhoef", "J. Metselaar", "G. Storm", "R. Kok" ],
      "venue" : "Int. J. Nanomed",
      "citeRegEx" : "Alaarg et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Alaarg et al\\.",
      "year" : 2016
    }, {
      "title" : "Bioavailability of curcumin: problems and promises",
      "author" : [ "P. Anand", "A.B. Kunnumakkara", "R.A. Newman", "B.B. Aggarwal" ],
      "venue" : "Mol. Pharm",
      "citeRegEx" : "Anand et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Anand et al\\.",
      "year" : 2007
    }, {
      "title" : "Preparation of lipid nanoemulsions incorporating curcumin for cancer therapy",
      "author" : [ "S. Anuchapreeda", "Y. Fukumori", "S. Okonogi", "H. Ichikawa" ],
      "venue" : "J. Nanotechnol",
      "citeRegEx" : "Anuchapreeda et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Anuchapreeda et al\\.",
      "year" : 2011
    }, {
      "title" : "Computer-based modeling of the conformation and packing properties of docosahexaenoic acid",
      "author" : [ "K.R. Applegate", "J.A. Glomset" ],
      "venue" : "J. Lipid Res",
      "citeRegEx" : "Applegate and Glomset,? \\Q1986\\E",
      "shortCiteRegEx" : "Applegate and Glomset",
      "year" : 1986
    }, {
      "title" : "Curcumin, a novel p300/CREB-binding protein-specific",
      "author" : [ "K. Balasubramanyam", "R.A. Varier", "M. Altaf", "V. Swaminathan", "N.B. Siddappa", "U. Ranga", "T.K. Kundu" ],
      "venue" : null,
      "citeRegEx" : "Balasubramanyam et al\\.,? \\Q2004\\E",
      "shortCiteRegEx" : "Balasubramanyam et al\\.",
      "year" : 2004
    }, {
      "title" : "Interaction of curcumin",
      "author" : [ "G. 51163–51171. Began", "E. Sudharshan", "K. Udaya Sankar", "A. Rao" ],
      "venue" : null,
      "citeRegEx" : "Began et al\\.,? \\Q1999\\E",
      "shortCiteRegEx" : "Began et al\\.",
      "year" : 1999
    }, {
      "title" : "Curcumin (diferuloylmethane) inhibits",
      "author" : [ "A.C. 4992–4997. Bharti", "N. Donato", "B.B. Aggarwal" ],
      "venue" : null,
      "citeRegEx" : "Bharti et al\\.,? \\Q2003\\E",
      "shortCiteRegEx" : "Bharti et al\\.",
      "year" : 2003
    }, {
      "title" : "The dietary pigment curcumin reduces endothelial",
      "author" : [ "R. Ziegler", "P. Nawroth" ],
      "venue" : null,
      "citeRegEx" : "N. et al\\.,? \\Q1997\\E",
      "shortCiteRegEx" : "N. et al\\.",
      "year" : 1997
    }, {
      "title" : "The influence of alkali fatty acids",
      "author" : [ "K. Buszello", "S. Harnisch", "R. Müller", "B. Müller" ],
      "venue" : null,
      "citeRegEx" : "Buszello et al\\.,? \\Q2000\\E",
      "shortCiteRegEx" : "Buszello et al\\.",
      "year" : 2000
    }, {
      "title" : "Angiogenesis in health and disease",
      "author" : [ "P. 284–289. Carmeliet" ],
      "venue" : "Nat. Med",
      "citeRegEx" : "Carmeliet,? \\Q2003\\E",
      "shortCiteRegEx" : "Carmeliet",
      "year" : 2003
    }, {
      "title" : "Oxidative stability",
      "author" : [ "S.Y. 14293–14311. Cho", "D.S. Joo", "H.G. Choi", "E. Naraand", "K. Miyashita" ],
      "venue" : null,
      "citeRegEx" : "Cho et al\\.,? \\Q2001\\E",
      "shortCiteRegEx" : "Cho et al\\.",
      "year" : 2001
    }, {
      "title" : "lipids from squid tissues",
      "author" : [ "D. Choudhury", "A. Ganguli", "D.G. Dastidar", "B.R. Acharya", "A. Das", "G. Chakrabarti" ],
      "venue" : "Fish. Sci",
      "citeRegEx" : "Choudhury et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Choudhury et al\\.",
      "year" : 2013
    }, {
      "title" : "Role of caveolae",
      "author" : [ "A.W. Cohen", "R. Hnasko", "W. Schubert", "M.P. Lisanti" ],
      "venue" : null,
      "citeRegEx" : "Cohen et al\\.,? \\Q2004\\E",
      "shortCiteRegEx" : "Cohen et al\\.",
      "year" : 2004
    }, {
      "title" : "Biological significance of essential fatty acids",
      "author" : [ "3390/jcm5020015. Das" ],
      "venue" : "U.N.,",
      "citeRegEx" : "10",
      "shortCiteRegEx" : "10",
      "year" : 2006
    }, {
      "title" : "Curcumin cyclodextrin combination for preventing or treating",
      "author" : [ "K. Desai" ],
      "venue" : null,
      "citeRegEx" : "Desai,? \\Q2010\\E",
      "shortCiteRegEx" : "Desai",
      "year" : 2010
    }, {
      "title" : "Phenolic and enolic hydroxyl groups in curcumin",
      "author" : [ "A2. Feng", "J.-Y", "Liu", "Z.-Q" ],
      "venue" : null,
      "citeRegEx" : "Feng et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Feng et al\\.",
      "year" : 2009
    }, {
      "title" : "Long-term effect of omega-3 fatty acid",
      "author" : [ "P. S0007114512001614. Geusens", "C. Wouters", "J. Nijs" ],
      "venue" : null,
      "citeRegEx" : "Geusens et al\\.,? \\Q1994\\E",
      "shortCiteRegEx" : "Geusens et al\\.",
      "year" : 1994
    }, {
      "title" : "Effective-loading of platinum-chloroquine",
      "author" : [ "S. bgh165. Ibrahim", "T. Tagami", "T. Ozeki" ],
      "venue" : null,
      "citeRegEx" : "Ibrahim et al\\.,? \\Q2017\\E",
      "shortCiteRegEx" : "Ibrahim et al\\.",
      "year" : 2017
    }, {
      "title" : "Inhibitory effects of docosahexaenoic acid on colon carcinoma",
      "author" : [ "H. Tsuda" ],
      "venue" : null,
      "citeRegEx" : "Tsuda,? \\Q1997\\E",
      "shortCiteRegEx" : "Tsuda",
      "year" : 1997
    }, {
      "title" : "membrane phospholipids and soybean lecithin",
      "author" : [ "D.A. Kuhn", "D. Vanhecke", "B. Michen", "F. Blank", "P. Gehr", "A. Petri-Fink" ],
      "venue" : "J. Dairy Sci",
      "citeRegEx" : "Kuhn et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Kuhn et al\\.",
      "year" : 2014
    }, {
      "title" : "Syntheses and evaluation of novel fatty acid-second-generation",
      "author" : [ "I. Ojima" ],
      "venue" : null,
      "citeRegEx" : "Ojima,? \\Q2006\\E",
      "shortCiteRegEx" : "Ojima",
      "year" : 2006
    }, {
      "title" : "Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis",
      "author" : [ "L. Li", "F. Braiteh", "R. Kurzrock" ],
      "venue" : "Cancer 104,",
      "citeRegEx" : "Li et al\\.,? \\Q2005\\E",
      "shortCiteRegEx" : "Li et al\\.",
      "year" : 2005
    }, {
      "title" : "Oxidative stability of marine phospholipids in the liposomal form and their applications",
      "author" : [ "F. Lu", "N. Nielsen", "M. Timm-Heinrich", "C. Acobsen" ],
      "venue" : "Lipids",
      "citeRegEx" : "Lu et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Lu et al\\.",
      "year" : 2011
    }, {
      "title" : "Physico-chemical properties of marine phospholipid emulsions",
      "author" : [ "F.S.H. Lu", "N.S. Nielsen", "C.P. Baron", "L.H.S. Jensen", "C. Jacobsen" ],
      "venue" : "JAOCS",
      "citeRegEx" : "Lu et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Lu et al\\.",
      "year" : 2012
    }, {
      "title" : "n-3 PUFA and membrane microdomains: a new frontier in bioactive lipid research",
      "author" : [ "D.W.L. Ma", "J. Seo", "K.C. Switzer", "Y.Y. Fan", "D.N. McMurray", "J.R. Lupton", "R.S. Chapkin" ],
      "venue" : "J. Nutr. Biochem",
      "citeRegEx" : "Ma et al\\.,? \\Q2004\\E",
      "shortCiteRegEx" : "Ma et al\\.",
      "year" : 2004
    }, {
      "title" : "Micelles of poly (ethylene oxide)-b-poly(e-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin",
      "author" : [ "Z. Ma", "A. Haddadi", "O. Molavi", "A. Lavasanifar", "R. Lai", "J. Samuel" ],
      "venue" : "J. Biomed. Mater. Res. A",
      "citeRegEx" : "Ma et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Ma et al\\.",
      "year" : 2007
    }, {
      "title" : "Small-volume extrusion apparatus for preparation of large, unilamellar vesicles",
      "author" : [ "R.C. MacDonald", "R.I. MacDonald", "B.P.M. Menco", "K. Takeshita", "N.K. Subbarao", "L. Hu" ],
      "venue" : null,
      "citeRegEx" : "MacDonald et al\\.,? \\Q1991\\E",
      "shortCiteRegEx" : "MacDonald et al\\.",
      "year" : 1991
    }, {
      "title" : "Effects of soluble factors and extracellular matrix components on vascular cell behavior in vitro and in vivo: models of de-endothelialization and repair",
      "author" : [ "J. Madri", "L. Bell", "M. Marx", "J. Merwin", "C. Basson", "C. Prinz" ],
      "venue" : "J. Cell. Biochem",
      "citeRegEx" : "Madri et al\\.,? \\Q1991\\E",
      "shortCiteRegEx" : "Madri et al\\.",
      "year" : 1991
    }, {
      "title" : "Curcuminphospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats",
      "author" : [ "K. Maiti", "K. Mukherjee", "A. Gantait", "B.P. Saha", "P.K. Mukherjee" ],
      "venue" : "Int. J. Pharm",
      "citeRegEx" : "Maiti et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Maiti et al\\.",
      "year" : 2007
    }, {
      "title" : "Curcumin and lung cancer—a review",
      "author" : [ "H.J. Mehta", "V. Patel", "R.T. Sadikot" ],
      "venue" : "Targeted Oncol",
      "citeRegEx" : "Mehta et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Mehta et al\\.",
      "year" : 2014
    }, {
      "title" : "Dietary ω-3 polyunsaturated fatty acid DHA: a potential adjuvant in the treatment of cancer",
      "author" : [ "N. Merendino", "L. Costantini", "L. Manzi", "R. Molinari", "D. D’Eliseo", "F. Velotti" ],
      "venue" : null,
      "citeRegEx" : "Merendino et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Merendino et al\\.",
      "year" : 2013
    }, {
      "title" : "Curcuminencapsulated MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy",
      "author" : [ "C. Mohanty", "S. Acharya", "A.K. Mohanty", "F. Dilnawaz", "S.K. Sahoo" ],
      "venue" : "Nanomedicine (London,",
      "citeRegEx" : "Mohanty et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Mohanty et al\\.",
      "year" : 2010
    }, {
      "title" : "Marinosomes®, marine lipid-based liposomes: physical characterization and potential application in cosmetics",
      "author" : [ "N. Moussaoui", "M. Cansell", "A. Denizot" ],
      "venue" : "Int. J. Pharm",
      "citeRegEx" : "Moussaoui et al\\.,? \\Q2002\\E",
      "shortCiteRegEx" : "Moussaoui et al\\.",
      "year" : 2002
    }, {
      "title" : "Optimized DPPH assay in a detergent-based buffer system for measuring antioxidant activity of proteins",
      "author" : [ "S.C.T. Nicklisch", "J.H. Waite" ],
      "venue" : "MethodsX",
      "citeRegEx" : "Nicklisch and Waite,? \\Q2014\\E",
      "shortCiteRegEx" : "Nicklisch and Waite",
      "year" : 2014
    }, {
      "title" : "Suppression of transcription factor Egr-1 by curcumin",
      "author" : [ "U. Pendurthi", "L. Rao" ],
      "venue" : "Thromb. Res",
      "citeRegEx" : "Pendurthi and Rao,? \\Q2000\\E",
      "shortCiteRegEx" : "Pendurthi and Rao",
      "year" : 2000
    }, {
      "title" : "Polyunsaturated fatty acid profiles of whole body phospholipids and triacylglycerols in anadromous and landlocked Atlantic salmon (Salmo salar L",
      "author" : [ "J. Peng", "Y. Larondelle", "D. Pham", "R.G. Ackman", "X. Rollin" ],
      "venue" : "fry. Comp. Biochem. Physiol. B: Biochem. Mol. Biol",
      "citeRegEx" : "Peng et al\\.,? \\Q2003\\E",
      "shortCiteRegEx" : "Peng et al\\.",
      "year" : 2003
    }, {
      "title" : "Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements",
      "author" : [ "R. Prior", "X. Wu", "K. Schaich" ],
      "venue" : "J. Agric. Food Chem",
      "citeRegEx" : "Prior et al\\.,? \\Q2005\\E",
      "shortCiteRegEx" : "Prior et al\\.",
      "year" : 2005
    }, {
      "title" : "Atherosclerosis and cancer: common molecular pathways of disease development and progression",
      "author" : [ "J.S. Ross", "N.E. Stagliano", "M.J. Donovan", "R.E. Breitbart", "G.S. Ginsburg" ],
      "venue" : "Ann. N.Y. Acad. Sci",
      "citeRegEx" : "Ross et al\\.,? \\Q2001\\E",
      "shortCiteRegEx" : "Ross et al\\.",
      "year" : 2001
    }, {
      "title" : "Structural properties of a highly polyunsaturated lipid bilayer from molecular dynamics simulations",
      "author" : [ "L. Saiz", "M.L. Klein" ],
      "venue" : "Biophys. J ",
      "citeRegEx" : "Saiz and Klein,? \\Q2001\\E",
      "shortCiteRegEx" : "Saiz and Klein",
      "year" : 2001
    }, {
      "title" : "The effect of omega-6 and omega-3 fatty acids on 3Hthymidine incorporation in hepatoma 7288CTC perfused in situ",
      "author" : [ "L.A. Sauer", "R.T. Dauchy" ],
      "venue" : "Br. J. Cancer",
      "citeRegEx" : "Sauer and Dauchy,? \\Q1992\\E",
      "shortCiteRegEx" : "Sauer and Dauchy",
      "year" : 1992
    }, {
      "title" : "Long-term supplementation with n-3 fatty acids, II: effect on neutrophil and monocyte chemotaxis",
      "author" : [ "E.B. Schmidt", "K. Varming", "J.O. Pedersen", "H.H. Lervang", "N. Grunnet", "C. Jersild", "J. Dyerberg" ],
      "venue" : "Scand. J. Clin. Lab. Invest",
      "citeRegEx" : "Schmidt et al\\.,? \\Q1992\\E",
      "shortCiteRegEx" : "Schmidt et al\\.",
      "year" : 1992
    }, {
      "title" : "The opposing effects of n-3 and n-6 fatty acids",
      "author" : [ "G. Schmitz", "J. Ecker" ],
      "venue" : "Prog. Lipid Res",
      "citeRegEx" : "Schmitz and Ecker,? \\Q2008\\E",
      "shortCiteRegEx" : "Schmitz and Ecker",
      "year" : 2008
    }, {
      "title" : "DPPH antioxidant assay revisited",
      "author" : [ "O.P. Sharma", "T.K. Bhat" ],
      "venue" : "Food Chem",
      "citeRegEx" : "Sharma and Bhat,? \\Q2009\\E",
      "shortCiteRegEx" : "Sharma and Bhat",
      "year" : 2009
    }, {
      "title" : "Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NFκB activation through inhibition of IκBα kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin",
      "author" : [ "S. Shishodia", "P. Potdar", "C.G. Gairola", "B.B. Aggarwal" ],
      "venue" : "D1. Carcinogenesis",
      "citeRegEx" : "Shishodia et al\\.,? \\Q2003\\E",
      "shortCiteRegEx" : "Shishodia et al\\.",
      "year" : 2003
    }, {
      "title" : "Loading of curcumin into macrophages using lipid-based nanoparticles",
      "author" : [ "K. Sou", "S. Inenaga", "S. Takeoka", "E. Tsuchida" ],
      "venue" : "Int. J. Pharm",
      "citeRegEx" : "Sou et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Sou et al\\.",
      "year" : 2008
    }, {
      "title" : "Modulation of angiogenesis by ω -3 polyunsaturated fatty acids is mediated by cyclooxygenases",
      "author" : [ "M. Szymczak", "M. Murray", "N. Petrovic", "W. Dc" ],
      "venue" : "Blood",
      "citeRegEx" : "Szymczak et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Szymczak et al\\.",
      "year" : 2008
    }, {
      "title" : "Simple and effective preparation of nano-pulverized curcumin by femtosecond laser ablation and the cytotoxic effect on C6 rat glioma cells in vitro",
      "author" : [ "T. Tagami", "Y. Imao", "S. Ito", "A. Nakada", "T. Ozeki" ],
      "venue" : "Int. J. Pharm",
      "citeRegEx" : "Tagami et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Tagami et al\\.",
      "year" : 2014
    }, {
      "title" : "Effective remote loading of doxorubicin into DPPC/Poloxamer 188 hybrid liposome to retain thermosensitive property and the assessment of carrier-based acute cytotoxicity for pulmonary administration",
      "author" : [ "T. Tagami", "M. Kubota", "T. Ozeki" ],
      "venue" : "J. Pharm",
      "citeRegEx" : "Tagami et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Tagami et al\\.",
      "year" : 2015
    }, {
      "title" : "Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin",
      "author" : [ "D. Thaloor", "A.K. Singh", "G.S. Sidhu", "P.V. Prasad", "H.K. Kleinman", "R.K. Maheshwari" ],
      "venue" : "Cell Growth Differ",
      "citeRegEx" : "Thaloor et al\\.,? \\Q1998\\E",
      "shortCiteRegEx" : "Thaloor et al\\.",
      "year" : 1998
    }, {
      "title" : "Marine polyunsaturated fatty acids and cancer therapy",
      "author" : [ "V.C. Vaughan", "Hassing", "M.-R", "P.A. Lewandowski" ],
      "venue" : "Br. J. Cancer",
      "citeRegEx" : "Vaughan et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Vaughan et al\\.",
      "year" : 2013
    }, {
      "title" : "Radical scavenging ability of polyphenolic compounds towards DPPH free radical",
      "author" : [ "D. Villaño", "M.S. Fernández-Pachón", "M.L. Moyá", "A.M. Troncoso", "M.C. García-Parrilla" ],
      "venue" : "Talanta",
      "citeRegEx" : "Villaño et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Villaño et al\\.",
      "year" : 2007
    }, {
      "title" : "Differential uptake of nanoparticles by endothelial cells through polyelectrolytes with affinity for caveolae",
      "author" : [ "J. Voigt", "J. Christensen", "V.P. Shastri" ],
      "venue" : "Proc. Natl. Acad. Sci. U.S.A",
      "citeRegEx" : "Voigt et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Voigt et al\\.",
      "year" : 2014
    }, {
      "title" : "Efficacy of dietary arachidonic acid provided as triglyceride or phospholipid as substrates for brain arachidonic acid accretion in baboon neonates",
      "author" : [ "V. Wijendran", "Huang", "M.-C", "Diau", "G.-Y", "G. Boehm", "P.W. Nathanielsz", "J.T. Brenna" ],
      "venue" : "Pediatr. Res",
      "citeRegEx" : "Wijendran et al\\.,? \\Q2002\\E",
      "shortCiteRegEx" : "Wijendran et al\\.",
      "year" : 2002
    }, {
      "title" : "Elucidation of phosphatidylcholine composition in krill oil extracted from Euphausia superba",
      "author" : [ "B. Winther", "N. Hoem", "K. Berge", "L. Reubsaet" ],
      "venue" : "Lipids",
      "citeRegEx" : "Winther et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Winther et al\\.",
      "year" : 2011
    }, {
      "title" : "The omega-3 polyunsaturated fatty acid docosahexaenoic acid inhibits proliferation and progression of non-small cell lung cancer cells through the reactive oxygen species-mediated inactivation of the PI3K/ Akt pathway",
      "author" : [ "Y. Yin", "C. Sui", "F. Meng", "P. Ma", "Y. Jiang" ],
      "venue" : "Lipids Health Dis",
      "citeRegEx" : "Yin et al\\.,? \\Q2017\\E",
      "shortCiteRegEx" : "Yin et al\\.",
      "year" : 2017
    } ],
    "referenceMentions" : [ {
      "referenceID" : 31,
      "context" : "Curcumin has been reported to target several molecules involved in the multistep carcinogenesis (Mehta et al., 2014).",
      "startOffset" : 96,
      "endOffset" : 116
    }, {
      "referenceID" : 6,
      "context" : "Additionally, curcumin modulates the expression of transcription factors to act as anti-proliferative, anti-inflammatory, anti-angiogenic and anti-metastatic agent (Balasubramanyam et al., 2004; Bharti et al., 2003; Bierhaus et al., 1997; Pendurthi and Rao, 2000; Shishodia et al., 2003).",
      "startOffset" : 164,
      "endOffset" : 287
    }, {
      "referenceID" : 8,
      "context" : "Additionally, curcumin modulates the expression of transcription factors to act as anti-proliferative, anti-inflammatory, anti-angiogenic and anti-metastatic agent (Balasubramanyam et al., 2004; Bharti et al., 2003; Bierhaus et al., 1997; Pendurthi and Rao, 2000; Shishodia et al., 2003).",
      "startOffset" : 164,
      "endOffset" : 287
    }, {
      "referenceID" : 36,
      "context" : "Additionally, curcumin modulates the expression of transcription factors to act as anti-proliferative, anti-inflammatory, anti-angiogenic and anti-metastatic agent (Balasubramanyam et al., 2004; Bharti et al., 2003; Bierhaus et al., 1997; Pendurthi and Rao, 2000; Shishodia et al., 2003).",
      "startOffset" : 164,
      "endOffset" : 287
    }, {
      "referenceID" : 45,
      "context" : "Additionally, curcumin modulates the expression of transcription factors to act as anti-proliferative, anti-inflammatory, anti-angiogenic and anti-metastatic agent (Balasubramanyam et al., 2004; Bharti et al., 2003; Bierhaus et al., 1997; Pendurthi and Rao, 2000; Shishodia et al., 2003).",
      "startOffset" : 164,
      "endOffset" : 287
    }, {
      "referenceID" : 3,
      "context" : "Despite the promising effects of curcumin against cancer and numerous diseases, its light sensitivity, poor solubility in aqueous medium and poor bioavailability are issues make it less useful as a therapeutic agent and have to be overcome in order to avail the entire benefits of this plant-extracted compound (Anand et al., 2007).",
      "startOffset" : 311,
      "endOffset" : 331
    }, {
      "referenceID" : 23,
      "context" : "using liposomes (Li et al., 2005), polymeric nanoparticles (Bisht et al.",
      "startOffset" : 16,
      "endOffset" : 33
    }, {
      "referenceID" : 46,
      "context" : ", 2007), lipid nanoparticles (Sou et al., 2008), nanoemulsions (Ahmed et al.",
      "startOffset" : 29,
      "endOffset" : 47
    }, {
      "referenceID" : 1,
      "context" : ", 2008), nanoemulsions (Ahmed et al., 2012), and cyclodextrins (Desai, 2010) have been extensively investigating in order to enhance drug solubility, bioavailability, the therapeutic efficacy and cause controlled release of the drug.",
      "startOffset" : 23,
      "endOffset" : 43
    }, {
      "referenceID" : 16,
      "context" : ", 2012), and cyclodextrins (Desai, 2010) have been extensively investigating in order to enhance drug solubility, bioavailability, the therapeutic efficacy and cause controlled release of the drug.",
      "startOffset" : 27,
      "endOffset" : 40
    }, {
      "referenceID" : 34,
      "context" : "Marinosomes are marine lipid-based liposomes containing a high ratio of polyunsaturated fatty acids (PUFAs) (Moussaoui et al., 2002).",
      "startOffset" : 108,
      "endOffset" : 132
    }, {
      "referenceID" : 43,
      "context" : "Marine PUFAs are divided into two subgroups: omega-6 (n-6) and omega-3 (n-3) that are metabolized and stored in cell membrane phospholipids (Schmitz and Ecker, 2008).",
      "startOffset" : 140,
      "endOffset" : 165
    }, {
      "referenceID" : 37,
      "context" : "In marine lipids, extracted from marine organisms like krill, a large portion of n-3 PUFAs are bound to phospholipids and includes a higher content of n-3 long chain PUFAs such as eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) (Peng et al., 2003; Winther et al., 2011).",
      "startOffset" : 257,
      "endOffset" : 298
    }, {
      "referenceID" : 55,
      "context" : "In marine lipids, extracted from marine organisms like krill, a large portion of n-3 PUFAs are bound to phospholipids and includes a higher content of n-3 long chain PUFAs such as eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) (Peng et al., 2003; Winther et al., 2011).",
      "startOffset" : 257,
      "endOffset" : 298
    }, {
      "referenceID" : 54,
      "context" : "Marine phospholipids have high bioavailability compared with triglyceride are efficiently taken up into body tissues (Wijendran et al., 2002).",
      "startOffset" : 117,
      "endOffset" : 141
    }, {
      "referenceID" : 51,
      "context" : "N-3 PUFAs have been used in the prevention and treatment of cancer through various mechanisms (Vaughan et al., 2013).",
      "startOffset" : 94,
      "endOffset" : 116
    }, {
      "referenceID" : 2,
      "context" : "A likely mechanism of cancer prevention through the anti-inflammatory properties of n-3 PUFAs has been reported (Alaarg et al., 2016).",
      "startOffset" : 112,
      "endOffset" : 133
    }, {
      "referenceID" : 56,
      "context" : "Other studies have reported different mechanisms of cancer prevention by n-3 PUFAs including apoptosis, inhibition of angiogenesis, inhibition of metastasis and others (Blanckaert et al., 2010; Iigo et al., 1997; Yin et al., 2017).",
      "startOffset" : 168,
      "endOffset" : 230
    }, {
      "referenceID" : 39,
      "context" : "Actually, n-3 PUFAs are not only beneficial in cancer treatment but also in other diseases that share the same common physiopathological features like unbalanced oxidative stress, inflammation and abnormal cell proliferation (Calder, 2012; Ross et al., 2001).",
      "startOffset" : 225,
      "endOffset" : 258
    }, {
      "referenceID" : 18,
      "context" : "Despite the promising effects of n-3 PUFAs against cancer and other numerous diseases, it has been reported that their effects are typically observed after long-term oral consumption at a relatively high amount (Geusens et al., 1994; Schmidt et al., 1992).",
      "startOffset" : 211,
      "endOffset" : 255
    }, {
      "referenceID" : 42,
      "context" : "Despite the promising effects of n-3 PUFAs against cancer and other numerous diseases, it has been reported that their effects are typically observed after long-term oral consumption at a relatively high amount (Geusens et al., 1994; Schmidt et al., 1992).",
      "startOffset" : 211,
      "endOffset" : 255
    }, {
      "referenceID" : 2,
      "context" : "The use of nanomedicine to increase the levels of n-3 PUFAs in inflamed tissues has been studied (Alaarg et al., 2016).",
      "startOffset" : 97,
      "endOffset" : 118
    }, {
      "referenceID" : 13,
      "context" : "Additionally, effective and low-cost anticancer combination drugs were developed from curcumin with other naturally occurring nutraceuticals (Choudhury et al., 2013).",
      "startOffset" : 141,
      "endOffset" : 165
    }, {
      "referenceID" : 19,
      "context" : "CURMs were prepared by reflux followed by thin drug-lipid film hydration method, which mentioned in details in our previous study with some modification (Ibrahim et al., 2017).",
      "startOffset" : 153,
      "endOffset" : 175
    }, {
      "referenceID" : 0,
      "context" : "The free radical scavenging activities of vitamin C, CURMs prepared by extrusion (CURME), CURMs prepared by sonication (CURMS), free curcumin (free-CUR) and free marinosomes (FMs) were determined using the 2,2-diphenyl-l-picrylhydrazyl (DPPH) assay as previously reported after modification (Aadinath et al., 2016).",
      "startOffset" : 291,
      "endOffset" : 314
    }, {
      "referenceID" : 35,
      "context" : "3% (v/v) Triton X-100 as previously reported after modification (Nicklisch and Waite, 2014).",
      "startOffset" : 64,
      "endOffset" : 91
    }, {
      "referenceID" : 49,
      "context" : "The cytotoxicity of the CURMS, free curcumin solution (free-CUR), and free marinosomes (FMS) were evaluated using a Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan) as previously described after modification (Tagami et al., 2015).",
      "startOffset" : 213,
      "endOffset" : 234
    }, {
      "referenceID" : 48,
      "context" : "In addition, the cells were treated with free-CUR, as a positive control, that was dissolved in ethanol and diluted by medium to the desired concentrations (0, 10, 20, 30, 40 μg/ml) as previously reported after modification (Tagami et al., 2014).",
      "startOffset" : 224,
      "endOffset" : 245
    }, {
      "referenceID" : 25,
      "context" : "natural surfactants to prepare emulsion without addition of other emulsifiers (Lu et al., 2012).",
      "startOffset" : 78,
      "endOffset" : 95
    }, {
      "referenceID" : 24,
      "context" : "Additionally, it was reported that the marine extracted lipids have a potential oxidative stability to prepare liposomes (Lu et al., 2011).",
      "startOffset" : 121,
      "endOffset" : 138
    }, {
      "referenceID" : 30,
      "context" : "raising the temperature melted the lipids and led to dissolve the curcumin into the lipid phase (Maiti et al., 2007).",
      "startOffset" : 96,
      "endOffset" : 116
    }, {
      "referenceID" : 7,
      "context" : "Additionally, curcumin could undergo hydrophobic interaction through its aromatic rings and hydrogen bonding through its phenol rings (Began et al., 1999).",
      "startOffset" : 134,
      "endOffset" : 154
    }, {
      "referenceID" : 28,
      "context" : "This is not surprising, as it is well known that the extruded vesicles would be close in diameter to the pore size of the polycarbonate membranes used to prepare them (MacDonald et al., 1991).",
      "startOffset" : 167,
      "endOffset" : 191
    }, {
      "referenceID" : 4,
      "context" : "4 nm, respectively, in agreement with what is previously reported (Anuchapreeda et al., 2011).",
      "startOffset" : 66,
      "endOffset" : 93
    }, {
      "referenceID" : 38,
      "context" : "In food and biological extracts, the standard DPPH (1,1-diphenyl-2picryl-hydrazyl) assay is accustomed to be used for the in vitro determination of antioxidant activity (Prior et al., 2005).",
      "startOffset" : 169,
      "endOffset" : 189
    }, {
      "referenceID" : 52,
      "context" : "The interaction kinetics of DPPH assay with polyphenolic and non-phenolic compounds have been recently well studied (Villaño et al., 2007).",
      "startOffset" : 116,
      "endOffset" : 138
    }, {
      "referenceID" : 35,
      "context" : "In the present study, a simple in vitro method to measure the antioxidant activity of liposomal formulations in buffer is used following a recent report after modification (Nicklisch and Waite, 2014).",
      "startOffset" : 172,
      "endOffset" : 199
    }, {
      "referenceID" : 44,
      "context" : "After determination of the antioxidant activity of ascorbic acid as a positive control using HBS-Triton mixture, shown in Table 3, we found that EC50 values agree with what was reported previously using methanol or buffered methanol solution (Sharma and Bhat, 2009).",
      "startOffset" : 242,
      "endOffset" : 265
    }, {
      "referenceID" : 12,
      "context" : "A synergistic antioxidant effect of phospholipid on α-tocopherol was previously reported (Cho et al., 2001).",
      "startOffset" : 89,
      "endOffset" : 107
    }, {
      "referenceID" : 12,
      "context" : "The third, the presumably synergistic antioxidant effect of phospholipid and α-tocopherol (Cho et al., 2001).",
      "startOffset" : 90,
      "endOffset" : 108
    }, {
      "referenceID" : 40,
      "context" : "It is well known that increasing the content of PUFA leads to increasing the fluidity of liposomes under physiological conditions compared to that of the saturated lipids (Saiz and Klein, 2001).",
      "startOffset" : 171,
      "endOffset" : 193
    }, {
      "referenceID" : 24,
      "context" : "In addition, nearly half of the PUFAs of krill lipid are located in phospholipids (mainly phosphatidyl-choline) as it is previously reported (Castro-Gómez et al., 2015; Lu et al., 2011).",
      "startOffset" : 141,
      "endOffset" : 185
    }, {
      "referenceID" : 33,
      "context" : "This means that free-CUR gives its ultimate effect on the cell during the early stage of the experiment and this may be due to the passive diffusion and accumulation of curcumin directly at its action site (Mohanty et al., 2010).",
      "startOffset" : 206,
      "endOffset" : 228
    }, {
      "referenceID" : 27,
      "context" : "This result clearly indicates the sustained release of curcumin from marinosomes over time that agrees with previous reports (Ma et al., 2007; Mohanty et al., 2010).",
      "startOffset" : 125,
      "endOffset" : 164
    }, {
      "referenceID" : 33,
      "context" : "This result clearly indicates the sustained release of curcumin from marinosomes over time that agrees with previous reports (Ma et al., 2007; Mohanty et al., 2010).",
      "startOffset" : 125,
      "endOffset" : 164
    }, {
      "referenceID" : 41,
      "context" : "It has been reported that PUFAs are taken up by tumors for use as precursors for biochemical metabolic pathways and energy production (Sauer and Dauchy, 1992).",
      "startOffset" : 134,
      "endOffset" : 158
    }, {
      "referenceID" : 32,
      "context" : "Once taken up, they are incorporated in the cellular membranes of the tumor and contribute to membrane fluidity, ion permeability and elasticity (Merendino et al., 2013).",
      "startOffset" : 145,
      "endOffset" : 169
    }, {
      "referenceID" : 26,
      "context" : "Plasma membrane is composed of microdomains that include structures known as lipid rafts and caveolae, which are rich in cholesterol and sphingolipids, and play a key role in cell signal transduction (Ma et al., 2004).",
      "startOffset" : 200,
      "endOffset" : 217
    }, {
      "referenceID" : 27,
      "context" : "It was reported that at a relatively high concentration (above 15 μg/ ml) of curcumin-loaded micelles, the cytotoxic effect was reduced due to saturation of the endocytic process which resulted in reduced drug entry (Ma et al., 2007; Mohanty et al., 2010).",
      "startOffset" : 216,
      "endOffset" : 255
    }, {
      "referenceID" : 33,
      "context" : "It was reported that at a relatively high concentration (above 15 μg/ ml) of curcumin-loaded micelles, the cytotoxic effect was reduced due to saturation of the endocytic process which resulted in reduced drug entry (Ma et al., 2007; Mohanty et al., 2010).",
      "startOffset" : 216,
      "endOffset" : 255
    }, {
      "referenceID" : 21,
      "context" : "Additionally, A549 cells were reported to employ multiple endocytotic pathways (Kuhn et al., 2014) that possibly localize CURMs in intracellular vesicles.",
      "startOffset" : 79,
      "endOffset" : 98
    }, {
      "referenceID" : 29,
      "context" : "The formation of new blood vessels is a natural process called angiogenesis and it is essential during wound healing and embryonic development (Madri et al., 1991).",
      "startOffset" : 143,
      "endOffset" : 163
    }, {
      "referenceID" : 11,
      "context" : "cluding tumor growth, are arising from uncontrolled angiogenesis (Carmeliet, 2003).",
      "startOffset" : 65,
      "endOffset" : 82
    }, {
      "referenceID" : 50,
      "context" : "It was reported that curcumin is able to inhibit the proliferation of HUVECs and act as anti-angiogenic compound (Thaloor et al., 1998).",
      "startOffset" : 113,
      "endOffset" : 135
    }, {
      "referenceID" : 14,
      "context" : "It was reported that the cellular membrane of endothelial cells is high in caveolae (Cohen et al., 2004) and that HUVEC cells express more caveolins than others (Voigt et al.",
      "startOffset" : 84,
      "endOffset" : 104
    }, {
      "referenceID" : 53,
      "context" : ", 2004) and that HUVEC cells express more caveolins than others (Voigt et al., 2014).",
      "startOffset" : 64,
      "endOffset" : 84
    }, {
      "referenceID" : 53,
      "context" : "This observation is previously used to target HUVEC cells using negatively charged lipid nanoparticles, without the need for cell-specific targeting ligands, depending on the high affinity of the lipophilic nanoparticles for caveolae (Voigt et al., 2014).",
      "startOffset" : 234,
      "endOffset" : 254
    } ],
    "year" : 2018,
    "abstractText" : "Lung cancer is the major cause of cancer-related death worldwide. Curcumin attracted attention due to its promising anti-cancer properties, however its poor aqueous solubility and bioavailability have to be overcome. In the current study curcumin is encapsulated in krill lipids-based liposomes (marinosomes) to develop a potential anticancer therapy from low-cost and readily available nutraceuticals. Reflux followed by thin drug-lipid film method is used successfully to incorporate the drug into the liposomal membrane at high encapsulation efficiency (EE). The curcumin-loaded marinosomes (CURMs) showed a powerful antioxidant activity (EC50≒ 4 μg/mL). Additionally, CURMs exhibited good physicochemical and oxidative stability after eight weeks’ storage at 4 °C. Furthermore, CURMs exhibited sustained release of about 30% of their curcumin content under in vitro culture conditions at 37 °C after 72 h. Consequently, CURMs showed its maximum cytotoxic effect (IC50; 11.7 ± 0.24 μg/ml) after incubation for 72 h against A549 lung cancer cells. Additionally, CURMs inhibited the proliferation of HUVECs in a dose-dependent manner with IC50 of 2.64 ± 0.21 μg/ml after incubation for 24 h. The current study presents the CURM as a favorable in vitro drug delivery system to target",
    "creator" : "Elsevier"
  }
}